{"id":270,"date":"2021-03-23T10:53:45","date_gmt":"2021-03-23T10:53:45","guid":{"rendered":"https:\/\/touchinfectiousdiseases.com\/?post_type=media_gallery&#038;p=270"},"modified":"2021-07-08T16:08:47","modified_gmt":"2021-07-08T15:08:47","slug":"tomas-hanke-hivr4p-2021-t-cell-vaccines-for-hiv-1-infection-part-1","status":"publish","type":"media_gallery","link":"https:\/\/touchinfectiousdiseases.com\/viral-infections\/conference-hub\/tomas-hanke-hivr4p-2021-t-cell-vaccines-for-hiv-1-infection-part-1\/","title":{"rendered":"Toma\u0301s\u030c Hanke, HIVR4P 2021: T cell Vaccines for HIV-1 Infection (Part 1)"},"content":{"rendered":"<p>We caught up with <strong>Tom\u00e1\u0161 Hanke<\/strong> (University of Oxford, Oxford, UK) to discuss T-cell vaccine strategies for the treatment of people with HIV-1 infection.<\/p>\n<p>His abstract entitled: \u2018Refocusing T cell responses with therapeutic vaccination strategies\u2019 (SY09.03) was presented at the HIVR4P Virtual Conference 2021, 04 February 2021.<\/p>\n<p>Part 2 of our discussion can be viewed <a href=\"https:\/\/touchinfectiousdiseases.com\/viral-infections\/conference-hub\/tomas-hanke-hivr4p-2021-t-cell-responses-in-hiv-to-inform-vaccine-development-part-2\/\">here<\/a>.<\/p>\n<p><strong>Questions<\/strong>:<\/p>\n<ol>\n<li>What is the rationale for developing T-cell vaccines for the treatment of people with HIV-1 infection? (0:19)<\/li>\n<li>What have been the greatest challenges to producing an effective and safe vaccine? (1:23)<\/li>\n<li>What vaccine strategies have proved most successful to date? (2:28)<\/li>\n<\/ol>\n<p><strong>Disclosures<\/strong>: Toma\u0301s\u030c Hanke is a QA coinventor on a patent protecting the use of the conserved mosaic vaccines.<\/p>\n<p><strong>Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.<\/p>\n<p><em><strong>Filmed in coverage of the HIVR4P Virtual Conference 2021.\u00a0<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>We caught up with Tom\u00e1\u0161 Hanke (University of Oxford, Oxford, UK) to discuss T-cell vaccine strategies for the treatment of people with HIV-1 infection. His abstract entitled: \u2018Refocusing T cell responses with therapeutic vaccination strategies\u2019 (SY09.03) was presented at the HIVR4P Virtual Conference 2021, 04 February 2021. Part 2 of our discussion can be viewed [&hellip;]<\/p>\n","protected":false},"featured_media":271,"template":"","class_list":["post-270","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-viral-infections","vocabulary_1-hiv","vocabulary_1-vaccines","video_categories-hivr4p-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchinfectiousdiseases.com\/wp-json\/wp\/v2\/media_gallery\/270"}],"collection":[{"href":"https:\/\/touchinfectiousdiseases.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchinfectiousdiseases.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":4,"href":"https:\/\/touchinfectiousdiseases.com\/wp-json\/wp\/v2\/media_gallery\/270\/revisions"}],"predecessor-version":[{"id":846,"href":"https:\/\/touchinfectiousdiseases.com\/wp-json\/wp\/v2\/media_gallery\/270\/revisions\/846"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchinfectiousdiseases.com\/wp-json\/wp\/v2\/media\/271"}],"wp:attachment":[{"href":"https:\/\/touchinfectiousdiseases.com\/wp-json\/wp\/v2\/media?parent=270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}